공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

특발성 폐섬유증(IPF) : 기회 분석과 예측(-2029년)

Idiopathic Pulmonary Fibrosis - Opportunity Analysis and Forecasts to 2029 (Event Driven Update)

리서치사 GlobalData
발행일 2021년 04월 상품 코드 970308
페이지 정보 영문 121 Pages
가격
US $ 10,995 ₩ 12,616,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 21,990 ₩ 25,233,000 PDF (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 32,985 ₩ 37,850,000 PDF (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


특발성 폐섬유증(IPF) : 기회 분석과 예측(-2029년) Idiopathic Pulmonary Fibrosis - Opportunity Analysis and Forecasts to 2029 (Event Driven Update)
발행일 : 2021년 04월 페이지 정보 : 영문 121 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

특발성 폐섬유증(IPF) 시장의 성장요인으로는 임상에서 미충족 요구를 충족하는 것을 목표로 하고 있는 제약기업에 의한 수익성 높은 치료제의 승인을 들 수 있으며, 현재의 치료법 보급과 신제품 승인의 증가가 예측 기간 중 이 시장 성장의 주요 추진력이 될 전망입니다.

주요 7개국(미국, EU 5개국, 일본)의 특발성 폐섬유증(IPF) 시장에 대해 조사했으며, 질환의 개요, 역학, COVID-19의 영향, 미충족 요구, 기회와 전략, 파이프라인 평가 분석 등의 정보를 정리하여 전해드립니다.

목차

제1장 목차

  • 표 리스트
  • 도표 리스트

제2장 개요

  • IPF 시장의 예측 기간 중 소극적인 성장
  • 혁신적인 소규모 제약기업의 개발을 유지하기 위한 제휴의 필요성
  • 높은 미충족 요구
  • 많은 다른 작용기서 중에서 혁신된 후기 파이프라인
  • 의사의 견해

제3장 서론

  • 촉매
  • 관련 리포트
  • 향후 관련 리포트

제4장 질환의 개요

  • 병인과 병태생리학
    • 병인
    • 병태생리학
  • 분류 또는 스테이징 시스템
    • GAP 모델
    • FVC(Forced Vital Capacity)의 저하에 의한 계층화

제5장 역학

  • 질병 배경
  • 위험인자와 병존 질환
  • 세계의 동향
  • 예측 조사 방법
  • IPF의 역학 예측(2019-2029)
    • IPF의 진단된 증례
    • IPF의 성별 진단 증례
    • IPF의 연령별 진단 증례
    • IPF의 진단된 유병률
    • 성별 : 진단된 IPF 유병률
    • 연령별 : 진단된 IPF 유병률
    • 중증도별 : IPF의 일반적인 증례 진단
    • 병존 질환별 : IPF의 일반적인 증례 진단
    • IPF 유병의률 합계
  • 토론
    • 역학적 예측 인사이트
    • COVID-19의 영향
    • 분석의 한계
    • 분석의 강점

제6장 현재의 치료 옵션

  • 개요
  • 현재의 치료 가이드라인
  • 증후성 치료

제7장 미충족 요구와 기회 평가

  • 개요
  • 조기진단
  • 의약품 안전성과 유효성의 향상
  • 환자의 삶의 질 개선
  • 중증 질병의 환자를 위한 치료

제8장 R&D 전략

  • 개요
    • 기업 제휴
    • 병용요법
  • 임상시험 디자인
    • 적절한 엔드포인트
    • 삶의 질 측정의 사용 증가
    • 표준 치료에 대한 애드온
    • 환자 집단의 선택

제9장 IPF 질환 공간에 대한 COVID-19의 영향

  • 개요
  • 케어의 지속성
  • 트라이얼 물류
  • 질병 공간에 대한 장기적인 영향

제10장 파이프라인 평가

  • 개요
  • 혁신적인 초기 단계 접근

제11장 파이프라인 평가 분석

  • 주요 파이프라인약의 임상 벤치마크
  • 주요 파이프라인약의 상업적 벤치마크
  • 경쟁력 있는 평가
  • 주요 라인의 10년간 예측
    • 미국
    • EU 5개국
    • 일본

제12장 부록

KSA 20.12.01

List of Tables

List of Tables

  • Table 1: IPF: Key Metrics in the 7MM
  • Table 2: The GAP Index
  • Table 3: Risk Factors and Comorbidities for IPF
  • Table 4: Diagnosed Prevalent Cases of IPF by Comorbidities, N, Both Sexes, Ages ≥18 Years, 2019
  • Table 5: Treatment Guidelines for IPF, 2020
  • Table 6: Leading Treatments for IPF, 2020
  • Table 7: Early Stage Pipeline Agents for IPF, 2020
  • Table 8: Clinical Benchmark of Key Pipeline Drugs - IPF
  • Table 9: Commercial Benchmark of Key Pipeline Drugs - IPF
  • Table 10: IPF Market - Global Drivers and Barriers, 2019-2029
  • Table 11: Key Events Impacting US Sales for IPF, 2019-2029
  • Table 12: Key Events Impacting 5EU Sales for IPF, 2019-2029
  • Table 13: Key Events Impacting Japan Sales for IPF, 2019-2029
  • Table 14: Key Historical and Projected Launch Dates for IPF
  • Table 15: Key Historical and Projected Patent Expiry Dates for IPF
  • Table 16: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

List of Figures

  • Figure 1: Global Sales Forecast by Country for IPF in 2019 and 2029
  • Figure 2: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the Standard of Care (SOC), Esbriet and Ofev
  • Figure 3: The Induction and Progression of IPF
  • Figure 4: 7MM, Diagnosed Incidence of IPF (Cases per 100,000 Population), Both Sexes, Ages ≥18 Years, 2019
  • Figure 5: 7MM, Diagnosed Prevalence of IPF, Both Sexes, Ages ≥18 Years, 2019
  • Figure 6: 7MM, Total Prevalence of IPF, Both Sexes, Ages ≥18 Years, 2019
  • Figure 7: 7MM, Sources Used and Not Used to Forecast the Diagnosed Incident and Diagnosed Prevalent Cases of IPF
  • Figure 8: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of IPF by Severity
  • Figure 9: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of IPF by Comorbidities
  • Figure 10: 7MM, Diagnosed Incident Cases of IPF, N, Both Sexes, Ages ≥18 Years, 2019
  • Figure 11: 7MM, Diagnosed Incident Cases of IPF, N, by Sex, Ages ≥18 Years, 2019
  • Figure 12: 7MM, Diagnosed Incident Cases of IPF by Age, N, Both Sexes, 2019
  • Figure 13: 7MM, Diagnosed Prevalent Cases of IPF, N, Both Sexes, Ages ≥18 Years, 2019
  • Figure 14: 7MM, Diagnosed Prevalent Cases of IPF, N, by Sex, Ages ≥18 Years, 2019
  • Figure 15: 7MM, Diagnosed Prevalent Cases of IPF by Age, N, Both Sexes, 2019
  • Figure 16: 7MM, Diagnosed Prevalent Cases of IPF by Severity, N, Both Sexes, Ages ≥18 Years, 2019
  • Figure 17: 7MM, Total Prevalent Cases of IPF, N, Both Sexes, Ages ≥18 Years, 2019
  • Figure 18: Unmet Needs and Opportunities in IPF
  • Figure 19: Overview of the Development Pipeline in IPF
  • Figure 20: Key Phase II/III Trials for Therapeutic Agents that Target IPF Disease Progression
  • Figure 21: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the Standard of Care (SOC)
  • Figure 22: Global (7MM) Sales Forecast by Country for IPF in 2019 and 2029
  • Figure 23: Global Sales Forecast by Molecule for IPF in 2019 and 2029
  • Figure 24: Sales Forecast by Class for IPF in the US in 2019 and 2029
  • Figure 25: Sales Forecast by Class for IPF in the 5EU in 2019 and 2029
  • Figure 26: Sales Forecast by Class for IPF in Japan in 2019 and 2029

Idiopathic pulmonary fibrosis (IPF) is the most common subtype of idiopathic interstitial pneumonias (IIPs), which belong to a group of rare diseases termed interstitial lung diseases (ILDs). Idiopathic pulmonary fibrosis (IPF) is a new and rapidly-establishing market, which, before 2011 was non-existent, with no approved pharmaceutical treatments for the chronic, debilitating disease, which has an abysmal prognosis. However, the last decade has seen a period of explosive growth in the IPF market following the entry of two pharmacological small molecule treatments; Roche's Esbriet and Boehringer Ingelheim's Ofev. The landscape will continue to evolve and the increasing uptake of current therapies and approval of new products will be the primary drivers of growth over the forecast period.

The catalyst for this event-driven update is the discontinuation of GLPG-1690 by Gilead/Galapagos for development in all indications, including IPF and Systemic Sclerosis (SSc) in Q1 2021. Due to IPF's high clinical unmet needs, the discontinuation of GLPG-1690 represents a major setback in the disease space, since ziritaxestat was expected to be the first late-state pipeline product to launch for IPF in the next several years. The next earliest pipeline agent set to launch is pamrevlumab in 2024.

Key Highlights

  • The greatest drivers of growth in the global IPF market include the launch of six new pipeline therapies during the forecast period and an increasing diagnosed prevalence in many 7MM countries.
  • The main barriers to growth in the IPF market include low diagnostic and treatment rates and the patent expiries of both Ofev and Esbriet in all markets.
  • The late-stage pipeline products are completely distinct mechanisms of action both from each other and the available marketed therapies.
  • The most important unmet needs in the IPF market are improved drug safety and efficacy and improvement in patient quality of life.

KEY QUESTIONS ANSWERED

  • Which unmet needs are limiting the treatment of IPF in the 7MM?
  • What strategies can the pharmaceutical industry employ to increase treatment rates for IPF? How should these strategies differ across different geographical markets?
  • What effect will the launch of generics have on the sales of branded agents?
  • What are the main R&D trends in the IPF market and which companies are leading the way? Are there major differences in the mechanisms of action used by therapies in late-stage versus early-stage clinical development?
  • What was the impact of the COVID-19 pandemic on the IPF treatment, clinical trial conduct, and looking forward?

Scope

  • Overview of IPF including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Topline IPF market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
  • Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting IPF therapeutics sales in the 7MM.
  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global IPF therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global IPF therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global IPF market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global IPF therapeutics market from 2019-2029.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Idiopathic Pulmonary Fibrosis: Executive Summary

  • 2.1 IPF Market to Experience Conservative Growth over the Forecast Period
  • 2.2 Innovative Small Pharma Require Partnerships to Sustain Development
  • 2.3 High Unmet Clinical Needs Remain
  • 2.4 Late-Stage Pipeline Fractured Among Many Differing Mechanisms of Action
  • 2.5 What Do Physicians Think?

3 Introduction

  • 3.1 Catalyst
  • 3.2 Related Reports
  • 3.3 Upcoming Related Reports

4 Disease Overview

  • 4.1 Etiology and Pathophysiology
    • 4.1.1 Etiology
    • 4.1.2 Pathophysiology
  • 4.2 Classification or Staging Systems
    • 4.2.1 GAP Model
    • 4.2.2 Stratification by Decline in Forced Vital Capacity (FVC)

5 Epidemiology

  • 5.1 Disease Background
  • 5.2 Risk Factors and Comorbidities
  • 5.3 Global and Historical Trends
  • 5.4 Forecast Methodology
    • 5.4.1 Sources Used
    • 5.4.2 Forecast Assumptions and Methods
  • 5.5 Epidemiological Forecast for IPF (2019-2029)
    • 5.5.1 Diagnosed Incident Cases of IPF
    • 5.5.2 Sex-Specific Diagnosed Incident Cases of IPF
    • 5.5.3 Age-Specific Diagnosed Incident Cases of IPF
    • 5.5.4 Diagnosed Prevalent Cases of IPF
    • 5.5.5 Sex-Specific Diagnosed Prevalent Cases of IPF
    • 5.5.6 Age-Specific Diagnosed Prevalent Cases of IPF
    • 5.5.7 Diagnosed Prevalent Cases of IPF by Severity
    • 5.5.8 Diagnosed Prevalent Cases of IPF by Comorbidities
    • 5.5.9 Total Prevalent Cases of IPF
  • 5.6 Discussion
    • 5.6.1 Epidemiological Forecast Insight
    • 5.6.2 Coronavirus Disease 2019 (COVID-19) Impact
    • 5.6.3 Limitations of Analysis
    • 5.6.4 Strengths of Analysis

6 Current Treatment Options

  • 6.1 Overview
  • 6.2 Current Treatment Guidelines
  • 6.3 Symptomatic Treatments

7 Unmet Needs and Opportunity Assessment

  • 7.1 Overview
  • 7.2 Earlier Diagnosis
  • 7.3 Improved Drug Safety and Efficacy
  • 7.4 Improvement in Patient Quality of Life
  • 7.5 Treatments for Patients with Severe Disease

8 R&D Strategies

  • 8.1 Overview
    • 8.1.1 Corporate Partnerships
    • 8.1.2 Combination Therapy
  • 8.2 Clinical Trial Design
    • 8.2.1 Appropriate Endpoints
    • 8.2.2 Increased Use of Quality of Life Measures
    • 8.2.3 Add-Ons to Standard of Care
    • 8.2.4 Selection of Patient Population

9 Impact of COVID-19 on the IPF Disease Space

  • 9.1 Overview
  • 9.2 Continuity of Care
  • 9.3 Trial Logistics
    • 9.3.1 Recruitment
    • 9.3.2 Trial Conduct in Isolation
    • 9.3.3 Supply Chain
  • 9.4 Long-Term Impact on the Disease Space

10 Pipeline Assessment

  • 10.1 Overview
  • 10.2 Innovative Early-Stage Approaches

11 Pipeline Valuation Analysis

  • 11.1 Clinical Benchmark of Key Pipeline Drugs
  • 11.2 Commercial Benchmark of Key Pipeline Drugs
  • 11.3 Competitive Assessment
  • 11.4 Top-Line 10-Year Forecast
    • 11.4.1 US
    • 11.4.2 5EU
    • 11.4.3 Japan

12 Appendix

  • 12.1 Bibliography
  • 12.2 Abbreviations
  • 12.3 Methodology
    • 12.3.1 Forecasting Methodology
    • 12.3.2 Diagnosed Patients
    • 12.3.3 Percent Drug-Treated Patients
    • 12.3.4 Drugs Included in Each Therapeutic Class
    • 12.3.5 Launch and Patent Expiry Dates
    • 12.3.6 General Pricing Assumptions
    • 12.3.7 Individual Drug Assumptions
    • 12.3.8 Generic Erosion
    • 12.3.9 Pricing of Pipeline Agents
  • 12.4 Primary Research - KOLs Interviewed for This Report
    • 12.4.1 KOLs
    • 12.4.2 Payers
  • 12.5 Primary Research - Prescriber Survey
  • 12.6 About the Authors
    • 12.6.1 Analyst
    • 12.6.2 Therapy Area Director
    • 12.6.3 Epidemiologist
    • 12.6.4 Managing Epidemiologist
    • 12.6.5 Global Director of Therapy Analysis and Epidemiology
    • 12.6.6 Global Head and EVP of Healthcare Operations and Strategy
  • 12.7 About GlobalData
  • 12.8 Contact Us
  • 12.9 Disclaimer
Back to Top
전화 문의
F A Q